Nautilus Biotechnology (NAUT) Cash from Operations (2020 - 2026)
Nautilus Biotechnology (NAUT) reported Cash from Operations of 13100000.0 for Q1 2026, up 6.01% on a YoY basis from 12357838.09 in Q1 2025, and down 5.86% sequentially from 12375000.0 in Q4 2025.
Nautilus Biotechnology (NAUT) Cash from Operations (2020 - 2026) Analysis & Trends
Nautilus Biotechnology (NAUT) has 7 years of Cash from Operations data on file, last reported at 13100000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 6.01% year-over-year to 13100000.0; the trailing twelve-month figure through Mar 2026 stood at 49859000.0 (up 12.24% YoY), and the FY2025 full-year result was 50696000.0, up 14.29% from the prior year.
- Cash from Operations slipped to 13100000.0 in Q1 2026, from 12375000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 9565000.0 in Q3 2022 to a low of 16266000.0 in Q1 2024.
- A 5-year average of 12968117.65 and a median of 13113000.0 in 2024 frame the typical range for Cash from Operations.
- Peak annual rise in Cash from Operations reached 32.53% in 2022, while the deepest fall reached 97.27% in 2022.
- Tracing NAUT's Cash from Operations over 5 years: stood at 10377000.0 in 2022, then tumbled by 33.95% to 13900000.0 in 2023, then fell by 2.94% to 14309000.0 in 2024, then gained by 13.52% to 12375000.0 in 2025, then declined by 5.86% to 13100000.0 in 2026.
- Business Quant data shows NAUT's Cash from Operations at 13100000.0 in Q1 2026, 12375000.0 in Q4 2025, and 11034000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Nautilus Biotechnology | 224.14 Mn | 224.14 Mn | - | -13.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.10 Mn |
| Mar 31, 2026 | -13.10 Mn |
| Dec 31, 2025 | -12.38 Mn |
| Dec 31, 2025 | -12.38 Mn |
| Sep 30, 2025 | -11.03 Mn |
| Sep 30, 2025 | -11.03 Mn |
| Jun 30, 2025 | -13.35 Mn |
| Jun 30, 2025 | -13.35 Mn |
| Mar 31, 2025 | -13.94 Mn |
| Mar 31, 2025 | -13.94 Mn |
| Dec 31, 2024 | -14.31 Mn |
| Dec 31, 2024 | -14.31 Mn |
| Sep 30, 2024 | -13.11 Mn |
| Sep 30, 2024 | -13.11 Mn |
| Jun 30, 2024 | -15.46 Mn |
| Jun 30, 2024 | -15.46 Mn |
| Mar 31, 2024 | -16.27 Mn |
| Mar 31, 2024 | -16.27 Mn |
| Dec 31, 2023 | -13.90 Mn |
| Dec 31, 2023 | -13.90 Mn |